Search results
Results from the WOW.Com Content Network
In patients with truly time-sensitive disease (defined in the 2014 ACC/AHA guidelines as needing to proceed in 2–6 weeks), DAPT can be stopped 3 (three) months (90 days) after a coronary stent is placed if postponing surgery any longer would result in significant morbidity. Examples of these types of surgeries include some cancer surgery and ...
A dual therapy stent is a coronary artery stent that combines the technology of an antibody-coated stent and a drug-eluting stent. [1] Currently, second-generation drug-eluting stents require long-term use of dual-antiplatelet therapy , which increases the risk of major bleeding occurrences in patients. [ 2 ]
At the present time, there is one temporary prostatic stent that has received U.S. Food and Drug Administration (FDA) approval. [4] The Spanner [5] temporary prostatic stent maintains urine flow and allows natural voluntary urination. The prostatic stent is a completely internal device and can be inserted and removed as easily as a Foley ...
Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. [10] It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). [10] It is taken by mouth. [10]
Increasing age, with the highest risk after ages 45 in men and 55 in women Being assigned male at birth Family history, especially having a genetic disorder called familial hypercholesterolemia
The most serious side effects associated with ticlopidine are those that affect the blood cells, although these life-threatening complications are relatively rare. The most common side effects include: [1] Diarrhea; Nausea; Dyspepsia; Rash; Abdominal pain; Ticlopidine may also cause an increase in cholesterol, triglycerides, liver enzymes, and ...
After placement of a stent or scaffold, the patient needs to take two antiplatelet medications (aspirin and one of a few other options) for several months to help prevent blood clots. The length of time a patient needs to be on dual antiplatelet therapy is individualized based risks of ischemic events and bleeding risk. [29]
Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure [5] and a decreased need for repeated coronary artery revascularization in the first month following the procedure.